B+
Bull case
20%
Probability
Target price
$425.00
Analysis reference price unavailable
Analysis 2026-01-23 · RankAlpha Sentiment AI
AMGN
AmgenDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$333.98
Analysis reference price unavailable
Analysis 2026-01-23 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$180.00
Analysis reference price unavailable
Analysis 2026-01-23 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-01-23
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+41.5
Score
AI commentary
Market tone is mixed: consensus median near $333.98 with a wide spread (low $180 to high $425), indicating divergent views on pipeline and biosimilar risk. Near-term sensitivity centers on the upcoming earnings window and late-stage readouts.
RankAlpha Sentiment AI - 2026-01-23
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-23catalystFY2025 Q4 earnings & guidanceMedium impact
Quarterly results and guidance update; market sensitivity to revenue, biologics demand, and buyback commentary.
2026-04-23catalystCapital-allocation update (buybacks/dividend)Medium impact
Management announcements on buybacks or dividend policy can re-rate shares and shift investor expectations.
2027-01-23eventLate-stage readouts & regulatory milestonesHigh impact
Potential late-stage trial readouts or FDA/EMA decisions; approvals lift value, failures or delays are negative.
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-23 • Updated nightlySource: Internal modelMethodology